| Document |
Document Title |
|
WO/2024/050567A2 |
Provided are peptides, modified peptides, fragments thereof, conjugates thereof, and polymers thereof that have antibacterial activity, including against multidrug-resistant bacteria. In some embodiments, the peptides include amino acid ...
|
|
WO/2024/046922A1 |
The present invention relates to a new composition comprising hydrolysed alpha-s1-casein and a fish protein hydrolysate, to the method for producing said composition and to the use of the composition in a food supplement, in solid or liq...
|
|
WO/2024/047130A1 |
Relaxin-2 for use as a broad-spectrum substitute of glucocorticoids, mineralocorticoids, corticosteroids and their analogues for treating tissue and endothelial injuries without incurring inducing gluconeogenesis, Cushing's syndrome and ...
|
|
WO/2024/049286A1 |
Provided are: a botulinum toxin formulation comprising a botulinum toxin in an amount corresponding to a desired titer; a preparation method therefor; a cosmetic or therapeutic method using same; and a method for reducing the immunogenic...
|
|
WO/2024/048795A1 |
The present invention provides: a conception chance-improving composition for normalization of EGF concentration profile and conception chance improvement for a ruminant; and a method for improving ruminant conception chance using said c...
|
|
WO/2024/050056A2 |
Provided are modified arginine deiminase (ADI) proteins, including ADI proteins that comprise one or more substitutions which increase expression in bacteria as insoluble and refoldable inclusion bodies. Also provided are methods of prod...
|
|
WO/2024/049280A1 |
The present invention relates to a composition for the prevention, alleviation, or treatment of fibrotic diseases, containing a Bacillus species strain, a Bacillus species strain spore, each expressing superoxide dismutase, and/or supero...
|
|
WO/2024/050026A2 |
Disclosed herein is a method of treating chronic and acute neuroinflammatory symptoms of a CNS disorder by administration of effective amounts of sublytic concentrations of a cholesterol dependent cytolysin (CDC).
|
|
WO/2024/045071A1 |
The present invention provides use of epidermal growth factor in preparing a medicament for treating interstitial cystitis. According to the present invention, epidermal growth factor (EGF) can be used to establish an interstitial cystit...
|
|
WO/2024/048683A1 |
The present invention provides a novel substance that suitably functions as an Met agonist. The present invention provides an artificial protein that includes an antibody Fc region, where an amino acid represented by SEQ ID NO: 1 is inse...
|
|
WO/2024/047219A1 |
The invention relates to haptoglobin or a nucleic acid encoding haptoglobin for use in treating or preventing of exaggerated erectile response and/or preventing permanent erectile dysfunction. In addition, the invention relates a pharmac...
|
|
WO/2024/050058A2 |
The present disclosure provides UL141 variants with one or more mutations, pharmaceutical compositions, diagnostic compositions, and kits containing the variants, nucleic acids and expression vectors encoding the variants, cells comprisi...
|
|
WO/2024/048748A1 |
The present invention provides an agent for inhibiting the progression of uremia in felids with severe renal failure, said agent containing an apoptosis inhibitor of macrophage (AIM), an AIM fragment having the biological activity of the...
|
|
WO/2024/049279A2 |
The present invention relates to sustained-release microspheres containing a high amount of leuprolide, an injectable preparation comprising same, and a preparation method therefor. During administration, leuprolide is released at a suff...
|
|
WO/2024/047134A1 |
The present invention relates to a use of collagen hydrolysate after intensive care unit (ICU) stay. The collagen hydrolysate improves the recovery and prevents and/or treats post intensive care syndrome (PICS) after ICU stay. The collag...
|
|
WO/2024/049227A1 |
The present invention relates to a composition for preventing or treating lupus or glomerulonephritis, comprising a recombinant stabilized galectin 9 protein. Specifically, it was confirmed that the recombinant stabilized galectin 9 prot...
|
|
WO/2024/050289A1 |
The present invention relates to a dosage form suitable for oral administration comprising a therapeutic peptide or protein in a sealed capsule having a co-polymer coating.
|
|
WO/2024/049204A1 |
The present invention relates to the use of a composition containing a zinc salt and cyclo-hispro (CHP) for the prevention, alleviation, or treatment of respiratory diseases and, more specifically, provides a composition for prevention, ...
|
|
WO/2024/050138A2 |
Compositions and methods for making and using engineered NK cells, T cells and B cells that express a chimeric antigen receptor.
|
|
WO/2024/046322A1 |
The present disclosure provides agonistic IL-15 complexes that have therapeutic use, and methods for making such proteins. The present disclosure additionally provides methods of treating disease in a subject in need thereof by administe...
|
|
WO/2024/049543A1 |
Compositions and methods are provided for in vivo or ex vivo delivery of a molecular cargo into endo-lysosomal compartments of LRP1-expressing cells. A molecular cargo of interest is linked to a substrate or inhibitor for recognition and...
|
|
WO/2023/247625A9 |
The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ...
|
|
WO/2024/048688A1 |
The present disclosure provides an opsin that has a light cycle characteristic. Specifically, the present disclosure provides a protein including an amino acid sequence of an opsin, wherein the amino acid sequence of the opsin includes a...
|
|
WO/2024/050007A1 |
Aspects of the disclosure relate to Botulinum toxin X (BoNT X) protein variants. The variants provided herein have been evolved to cleave GTP cyclohydrolase 1 (GCH1). Some of the variants provided herein were evolved from a procaspase- 1...
|
|
WO/2024/050300A2 |
Compositions and methods are described that are useful for treating and preventing viral infections, such as those by SARS-CoV-2. It is discovered herein that synthetic surfactants such as SMB (SEQ ID NO:7) and B-YL (SEQ ID NO:27) can bi...
|
|
WO/2024/046301A1 |
The present disclosure provides a fusion protein comprising a TACI polypeptide and a use thereof, particularly a use for preventing or treating autoimmune diseases.
|
|
WO/2024/047237A1 |
The application relates to the treatment of cancer, including non-melanoma skin cancer. The invention involves the use of a tumor necrosis factor alpha (TNFα) immunoconjugate and an interleukin 2 (IL2) immunoconjugate in a combination t...
|
|
WO/2024/044822A1 |
Provided herein are pharmaceutical compositions comprising an active agent which is a soluble VEGFR-3 trap molecule. Also provided herein are therapeutic methods and uses involving the pharmaceutical compositions, in particular ocular di...
|
|
WO/2024/049906A1 |
Therapeutic compositions for treating a subject, the compositions including a polymeric nanoparticle, an active agent encapsulated within the polymeric nanoparticle, and a delivery vehicle for targeted delivery of the polymeric nanoparti...
|
|
WO/2024/050464A2 |
Described herein are compositions and methods for treating, preventing, reducing the likelihood of having, reducing the severity of and/or slowing the progression of ischemia-reperfusion injury in a subject using GJA1-20k as a therapeuti...
|
|
WO/2024/050145A1 |
Disclosed herein are methods of administering thiostrepton, or pharmaceutical compositions thereof, as well as methods of treating cancer.
|
|
WO/2024/047655A1 |
Methods for inhibiting or preventing activation of a macrophage, by a receptor antagonist of α9β1 integrin are provided. Further provided are methods for treating or preventing an inflammatory disease or a metabolic disorder, including...
|
|
WO/2024/044560A2 |
A novel composition and method of enhancing wound healing and minimizing rejection of an implant is presented. The composition is a dry acellular mixture comprised of conditioned media from mesenchymal stem cells, a multifunctional prote...
|
|
WO/2024/042466A1 |
Polypeptides that traverse the blood-brain-barrier (BBB) are disclosed. The peptide can serve as BBB-traversing transport vehicles for delivering active agents from the circulation into across the BBB to contact cells and tissues within ...
|
|
WO/2024/043716A1 |
The present invention relates to a cosmetic or pharmaceutical composition containing, as active ingredients, microvesicles isolated from culture media of natural killer cells, induced pluripotent stem cells, or mesenchymal stem cells, hy...
|
|
WO/2024/042168A1 |
The present invention provides novel RNA-guided nuclease proteins and nucleic acid targeting system comprising such for cleaving and/or modifying the target nucleotide of interest.
|
|
WO/2024/040356A1 |
Provided herein are pharmaceutical dosage forms for delivering peptide therapeutics to a mucosal surface. The pharmaceutical dosage forms comprise a mucoadhesive layer; a peptide loading layer; and a water impermeable layer, wherein the ...
|
|
WO/2024/042930A1 |
The purpose of the present invention is to provide a pharmaceutical composition and the like for treating or preventing inflammation caused by Acanthamoeba. Specifically provided are a pharmaceutical composition for treating or preventin...
|
|
WO/2024/042554A1 |
The present invention relates to pharmaceutical composition comprising (i) a peroxisome proliferator-activated receptor (PPAR) activating fatty acid and/or a cathelicidin (LL37) compound, its precursors or analogue thereof; (ii) a vitami...
|
|
WO/2024/043975A1 |
The present invention provides novel compositions and methods for inducing and/or activating regulatory T cells (Treg). Wherein a method of treating, inhibiting, and/or preventing a disease or disorder in a subject in need thereof, said ...
|
|
WO/2024/044680A2 |
Therapeutic regimens and uses of mutant Fibroblast Growth Factor-21 (FGF-21) peptide conjugates in the treatment of nonalcoholic steatohepatitis are provided.
|
|
WO/2024/041236A1 |
A fusion protein ANGPTL3 monoclonal antibody-B comprising an ANGPTL3 monoclonal antibody is formed by fusing the ANGPTL3 monoclonal antibody with a sequence B. The fusion protein ANGPTL3 monoclonal antibody-B is used for treating disease...
|
|
WO/2024/041172A1 |
To solve the problem that existing microneedles cannot achieve continuous and controllable adjustment of blood glucose and are prone to breakage to cause inflammation and infection in the skin, a microneedle for treating diabetes is prov...
|
|
WO/2024/042220A1 |
The present invention relates to isolated polypeptides derived from stanniocalcin-2 (STC2), and polypeptide fragments and variants thereof useful for inhibiting proteolytic activity of the pregnancy-associated plasma protein-A (PAPP-A), ...
|
|
WO/2024/043713A1 |
The present invention relates to: a composition comprising a natural killer cell-derived exosome and a biocompatible polymer as active ingredients; and a use thereof. The composition according to the present invention exhibits excellent ...
|
|
WO/2024/044780A1 |
The present disclosure provides IL-18 polypeptides with one or more mutations, pharmaceutical compositions, diagnostic compositions, and kits containing the polypeptides, nucleic acids and expression vectors encoding the polypeptides, ce...
|
|
WO/2024/040322A1 |
The present invention involves biomimetic peptides derived from the multifunctional factor thymosin-B4 (TB4) functionalized with serotonin (5-HT- or 5-hydroxytryptamine) and/or its biological precursor 5-hydroxytryptophan (5-HTP*). More ...
|
|
WO/2024/044659A1 |
Provided herein are methods of inhibiting immune cell activation or inflammatory cytokine production by an immune cell in a subject. The methods involve introducing into an immune cell of the subject a polynucleotide encoding a constitut...
|
|
WO/2024/044697A2 |
Disclosed herein are novel compositions and methods for the treatment of Fabry disease, including therapeutic proteins with enhanced α-galactosidase (α-GAL) activity and engineered B cells edited to express modified therapeutic protein...
|
|
WO/2024/044748A2 |
Provided according to some embodiments is a compound of Formula I, or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions comprising the same and methods of use for treating cancer and inhibiting PRX3 are also provided.
|
